US EditionPublished • loading... • Updated
Immunotherapy review highlights Faron’s bexmarilimab in immune-resistant cancer - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Immunotherapy review highlights Faron’s bexmarilimab in immune-resistant cancer - BioTuesdays
Faron Pharmaceuticals (AIM: FARN; First North: FARON) has announced the publication of a comprehensive review article in the peer-reviewed journal Immunotherapy detailing the potential of the company’s lead candidate, bexmarilimab, to overcome immune resistance in cancer. The article, titled Clinical optimization of bexmarilimab as a myeloid checkpoint therapy, outlines how inhibition of Clever-1—a scavenger receptor expressed on immunosuppressi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
